OBJECTIVE The Radixact Synchrony system allows for target motion correction when tracking either fiducials in/around the target or a dense lesion in the lung. As such evaluation testing and quality assurance (QA) tests are required. METHODS To allow for QA procedures to be performed with a range of available phantoms evaluation of the dosimetric delivery accuracy was performed for a range of motions, phantoms, and motion platforms. A Computerized Imaging Reference Systems, Incorporated (CIRS) 1D motion platform and Accuray Tomotherapy "Cheese" phantom was utilized to perform absolute dose and GafChromic EBT3 film measurements. A HexaMotion platform and Delta4 phantom were utilized to quantify the effects of 1D and 3D motions. Inter-device comparison was performed with the ArcCHECK and Delta4 phantoms and GafChromic EBT3 film, five patient plans were delivered to each phantom when static and with two different motion types both with and without Synchrony motion correction. RESULTS A range of QA tests are described. A phantom was designed to allow for daily verification of system functionality. This test allows for the detection of either fiducials or a dense silicone target with a stationary phantom. Monthly testing procedures are described that allow the user to verify the dosimetric improvement when utilizing synchrony delivery motion compensation versus uncorrected motions. These can be performed utilizing a 1D motion stage with an ion-chamber and GafChromic EBT3 film to allow for a 2D dosimetric validation. Alternatively, a 3D motion platform can be utilized where available. Monthly and annual imaging tests are described. Finally, annual test procedures designed to verify the coincidence of the imaging system and treatment isocenter are described. The evaluation of the Synchrony system using a range of QA devices shows consistently high dosimetric accuracy with similar trends in passing criteria found with GafChromic EBT3 film, ArcCHECK, and Delta4 phantoms for density-based respiratory model compensation. CONCLUSIONS These results highlight the large improvements in the dose distribution when motion is accounted for with the Synchrony system as measured with a range of phantoms and motion platforms that the majority of users will have available. The testing methods and QA procedures described provide guidance for new users of the Radixact Synchrony system as they implement their own QA programs for this system, until such time as an AAPM task group report is made available. QA procedures including Kilovolts (kV) imaging quality metrics and imaging dose parameters, dose deposition accuracy, target detection coincidence, and target position detection accuracy are described.